



Share documents. Simply, securely.

New Webinar:

Gene & Cell Therapies - It's Show Time!

January 16th, at 11 am

Until recently, the concept that the genetic status of an individual was fixed and unalterable was widely accepted. However, in the last several years, advances in human genetics, cell biology, and gene therapy have resulted in a fundamental change in this therapeutic paradigm. Today's physicians are not only using gene and cell therapies to help patients live better with their genetic constitutions, but are also using novel therapies to alter the genetic makeup of the patient.

In the upcoming webinar, [Mike Rice of Defined Health](#) will discuss recent advances in gene and stem cell therapies with particular emphasis on the therapeutic potentials and the significant hurdles that must be overcome for effective treatment of diseases.

Breakthrough gene and cell therapies for ultra-rare disorders are expected to gain FDA approval in the next couple of years including:

- Spark Therapeutics' gene therapy for inherited retinal dystrophies (in vivo)
- Bluebird

- Bio's Lentiviral transduced HSCs for β Thalassemia (ex vivo)
- Roche's bispecific monoclonal antibody, emicizumab, which dramatically decreases bleeding events in hemophiliacs

Join the webinar from the comfort of your desk on Tuesday, **January 16th, 2018** to explore the potential, advances and availability of these therapies and the implications that "one-time treatments" will have on pricing, risk-sharing schemes, and ultimately, market valuations and deal making.

[Register](#) for this webinar.

Sam Taylor, President
North Carolina Biosciences Organization
P.O. Box 14354
Research Triangle Park, NC 27709
staylor@ncbioscience.net



You are receiving this announcement as part of your NCBIO membership. If you do not wish to receive announcements, please click the unsubscribe link provided below.

NCBIO | PO Box 14345 | Research Triangle Park, NC 27709